The purpose of this study is to evaluate efficacy, safety of administered DWP05195 in Postherpetic Neuralgia.

Inclusion Criteria:

• Male or Female subjects aged 20 to 80 years
• Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN).
• Subjects must have pain present for > 3 months after healing of the acute herpes zoster skin rash.

Exclusion Criteria:

• Other severe pain that may potentially confound pain assessment.
• Subjects with symptoms of neuropathic pain applied Medical Equipment
• Within 2 years: Subjects were diagnosed with cancer